Prasad
Biotech

CBER Director Vinay Prasad to depart FDA—again

Prasad has drawn increased criticism throughout his tenure, especially from the rare disease community.
Darren Incorvaia Mar 6, 2026 5:30pm
FDA conference hall

FDA to end 9-month adcomm hiatus with review of AZ's cancer drugs

Mar 6, 2026 11:16am
How physiology powers biotech innovation

How physiology powers biotech innovation

Brought to you by American Physiological Society
team layoffs workforce

Alltrna CEO departs amid 35% layoff round

Mar 6, 2026 8:30pm
FDA stop sign

Senior FDA official fires back at uniQure amid controversy

Mar 5, 2026 3:33pm
gymnastics

Zealand's Zupreme serves up to 10.7% mean weight loss

Mar 5, 2026 4:44pm
More News

Fierce Biotech Layoff Tracker 2026: Vertex, Alltrna & more

Mar 6, 2026 4:00pm
Fierce Pharma

Servier rounds out rare cancer offerings with $2.5B Day One buy

Mar 6, 2026 10:14am

Bavarian Nordic CEO exits after failed takeover—Chutes & Ladders

Mar 6, 2026 8:30am

Beam rejigs deal to retain technology amid partner's dissolution

Mar 6, 2026 8:20am